Steven M. Paul

This profile gathers the share dealings of Steven M. Paul across 7 companies, led by Sage Therapeutics, Inc., ELI LILLY & Co and Karuna Therapeutics, Inc. Between 20 January 2006 and 22 October 2026, the trades on record add up to 168 filings.

On the open market, the record shows 10 purchases worth €2.5M and 79 sales worth €71.1M. Netting one side against the other leaves €68.6M of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 23 share grants and 13 option exercises. Since January 2026: 1 purchase and no sales on the market.

In size, the median ticket on the buying side is €131k. Clusters matter here: 3 out of 8 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster. For 4 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 75% of cases, with a median move of +10.8%. They describe history only and say nothing certain about the share price ahead.

The newest entry dates from 22 October 2026: an open-market purchase of €867k, in Rapport Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.